Evaxion将于2026年5月7日发布业务进展及第一季度财务业绩

投资观察

May 04

临床阶段科技生物公司Evaxion Biotech A/S（纳斯达克代码：EVAX）宣布，将于2026年5月7日（周四）纳斯达克资本市场开盘前，公布2026年第一季度财务报告及最新业务动态。

公司高管团队将于同日欧洲中部时间14:30（美国东部时间08:30）举行电话会议及网络直播，详细介绍业务进展与财务数据，并现场回应提问。

欲参与电话会议、收听演讲并进行口头提问，请提前通过指定链接完成注册以获取拨入号码及专属密码。会议开始前15分钟即可接入系统。

参与网络直播请点击相关链接。活动结束后，录播内容将迅速发布于公司官网。

Evaxion Biotech A/S是一家以前沿AI免疫学平台为核心的创新型科技生物企业。该平台通过人工智能技术解析人体免疫系统，致力于开发针对癌症和传染病的创新疫苗候选药物。

依托AI免疫学平台，公司实现了高效精准的靶点发现、药物设计与开发全流程。超过40名专家组成的团队覆盖从靶点识别到临床开发的全产业链环节。

目前公司已建立包含个性化/通用型癌症疫苗、传染病预防疫苗在内的临床研发管线。所有候选药物均聚焦于未满足的临床需求，彰显了通过创新靶向治疗方案改善患者生命的坚定承诺。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1126261705"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126261705\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126261705?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-05-04 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126261705","market":"hk","top_or_hot":-1,"title":"Evaxion将于2026年5月7日发布业务进展及第一季度财务业绩","media":"投资观察","content":"<p>临床阶段科技生物公司Evaxion Biotech A/S（纳斯达克代码：EVAX）宣布，将于2026年5月7日（周四）纳斯达克资本市场开盘前，公布2026年第一季度财务报告及最新业务动态。</p>\n<p>公司高管团队将于同日欧洲中部时间14:30（美国东部时间08:30）举行电话会议及网络直播，详细介绍业务进展与财务数据，并现场回应提问。</p>\n<p>欲参与电话会议、收听演讲并进行口头提问，请提前通过指定链接完成注册以获取拨入号码及专属密码。会议开始前15分钟即可接入系统。</p>\n<p>参与网络直播请点击相关链接。活动结束后，录播内容将迅速发布于公司官网。</p>\n<p>Evaxion Biotech A/S是一家以前沿AI免疫学平台为核心的创新型科技生物企业。该平台通过人工智能技术解析人体免疫系统，致力于开发针对癌症和传染病的创新疫苗候选药物。</p>\n<p>依托AI免疫学平台，公司实现了高效精准的靶点发现、药物设计与开发全流程。超过40名专家组成的团队覆盖从靶点识别到临床开发的全产业链环节。</p>\n<p>目前公司已建立包含个性化/通用型癌症疫苗、传染病预防疫苗在内的临床研发管线。所有候选药物均聚焦于未满足的临床需求，彰显了通过创新靶向治疗方案改善患者生命的坚定承诺。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evaxion将于2026年5月7日发布业务进展及第一季度财务业绩</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvaxion将于2026年5月7日发布业务进展及第一季度财务业绩\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1076224072\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">投资观察 </p>\n<p class=\"h-time\">2026-05-04 20:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>临床阶段科技生物公司Evaxion Biotech A/S（纳斯达克代码：EVAX）宣布，将于2026年5月7日（周四）纳斯达克资本市场开盘前，公布2026年第一季度财务报告及最新业务动态。</p>\n<p>公司高管团队将于同日欧洲中部时间14:30（美国东部时间08:30）举行电话会议及网络直播，详细介绍业务进展与财务数据，并现场回应提问。</p>\n<p>欲参与电话会议、收听演讲并进行口头提问，请提前通过指定链接完成注册以获取拨入号码及专属密码。会议开始前15分钟即可接入系统。</p>\n<p>参与网络直播请点击相关链接。活动结束后，录播内容将迅速发布于公司官网。</p>\n<p>Evaxion Biotech A/S是一家以前沿AI免疫学平台为核心的创新型科技生物企业。该平台通过人工智能技术解析人体免疫系统，致力于开发针对癌症和传染病的创新疫苗候选药物。</p>\n<p>依托AI免疫学平台，公司实现了高效精准的靶点发现、药物设计与开发全流程。超过40名专家组成的团队覆盖从靶点识别到临床开发的全产业链环节。</p>\n<p>目前公司已建立包含个性化/通用型癌症疫苗、传染病预防疫苗在内的临床研发管线。所有候选药物均聚焦于未满足的临床需求，彰显了通过创新靶向治疗方案改善患者生命的坚定承诺。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4099","symbol_name":"汽车制造商","start_time":0,"source_url":"","article_id":"1126261705","we_media_id":"1076224072","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126261705","pubTimestamp":1777896261,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"投资观察","introduction":"关注海外资本市场一手动态","home_visible":1,"id":"1076224072","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"临床阶段科技生物公司Evaxion Biotech A/S宣布，将于2026年5月7日（周四）纳斯达克资本市场开盘前，公布2026年第一季度财务报告及最新业务动态。公司高管团队将于同日欧洲中部时间14:30举行电话会议及网络直播，详细介绍业务进展与财务数据，并现场回应提问。Evaxion Biotech A/S是一家以前沿AI免疫学平台为核心的创新型科技生物企业。所有候选药物均聚焦于未满足的临床需求，彰显了通过创新靶向治疗方案改善患者生命的坚定承诺。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4099":"汽车制造商","AGIX":"通用人工智能 ETF-AGIX","AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4555":"新能源车","ARTY":"ISHARES FUTURE AI & TECH ETF","TM":"丰田汽车","BK4587":"ChatGPT概念","BK4528":"SaaS概念","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","AI":"C3.ai, Inc.","BK4588":"碎股","BK4551":"寇图资本持仓","03160":"华夏日股对冲","BK4023":"应用软件","AIPO":"Defiance AI and Power Infrastructure ETF","BK4604":"机器人概念","BK4543":"AI","EVAX":"Evaxion Biotech A/S"},"translate_title":"Evaxion to Release Business Progress and First Quarter Financial Results on May 7, 2026","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TM":1,"AGIX":1,"AIYY":1,"AIPO":1,"03160":1,"EVAX":1,"CHAT":1,"ARTY":1,"AI":1},"content_text":"临床阶段科技生物公司Evaxion Biotech A/S（纳斯达克代码：EVAX）宣布，将于2026年5月7日（周四）纳斯达克资本市场开盘前，公布2026年第一季度财务报告及最新业务动态。\n公司高管团队将于同日欧洲中部时间14:30（美国东部时间08:30）举行电话会议及网络直播，详细介绍业务进展与财务数据，并现场回应提问。\n欲参与电话会议、收听演讲并进行口头提问，请提前通过指定链接完成注册以获取拨入号码及专属密码。会议开始前15分钟即可接入系统。\n参与网络直播请点击相关链接。活动结束后，录播内容将迅速发布于公司官网。\nEvaxion Biotech A/S是一家以前沿AI免疫学平台为核心的创新型科技生物企业。该平台通过人工智能技术解析人体免疫系统，致力于开发针对癌症和传染病的创新疫苗候选药物。\n依托AI免疫学平台，公司实现了高效精准的靶点发现、药物设计与开发全流程。超过40名专家组成的团队覆盖从靶点识别到临床开发的全产业链环节。\n目前公司已建立包含个性化/通用型癌症疫苗、传染病预防疫苗在内的临床研发管线。所有候选药物均聚焦于未满足的临床需求，彰显了通过创新靶向治疗方案改善患者生命的坚定承诺。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}